Evidence map›Paper›PMID 33565902›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2021

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

J Das, J A Snowden, J Burman, M S Freedman, H Atkins, M Bowman, R K Burt, R Saccardi, C Innocenti, S Mistry and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. The EBMT-ADWP and the CIBMTR.Handbook of clinical neurology · 2024
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J DasSheffield Institute for Translational Neuroscience, University of Sheffield, UK/Academic Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.ORCID 0000-0002-9166-4624
J A SnowdenDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
J BurmanDepartment of Neurology, Uppsala University Hospital, Uppsala, Sweden.ORCID 0000-0002-7045-1806
M S FreedmanDepartment of Medicine (Neurology), The University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
H AtkinsDepartment of Medicine (Neurology), The University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
M BowmanDepartment of Medicine (Neurology), The University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
R K BurtDivision of Immunotherapy, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
R SaccardiDepartment of Cellular Therapies and Transfusion Medicine, Careggi University Hospital, Florence, Italy.
C InnocentiDepartment of Cellular Therapies and Transfusion Medicine, Careggi University Hospital, Florence, Italy.
S MistryAcademic Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.ORCID 0000-0002-6144-1999
P J LaudStatistical Services Unit, University of Sheffield, Sheffield, UK.
H JessopDepartment of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
B SharrackAcademic Department of Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Institute for Translational Neuroscience, University of Sheffield, UK.

Funding

Department of Health
6 · The paper itself

Abstract

backgroundAutologous haematopoietic stem cell transplantation (AHSCT) is an effective treatment for patients with multiple sclerosis (MS) who have highly active disease, despite the use of standard disease-modifying therapies (DMTs). However, the optimal time for offering AHSCT to patients with 'aggressive' MS is yet to be established.

objectivesThe objective was to explore the safety and efficacy of AHSCT as a first-line DMT in patients with 'aggressive' MS.

methodsAll patients with 'aggressive' MS who received AHSCT as a first-line DMT in five European and North American centres were retrospectively evaluated.

resultsTwenty patients were identified. The median interval between diagnosis and AHSCT was 5 (1-20) months. All had multiple poor prognostic markers with a median pre-transplant Expanded Disability Status Scale (EDSS) score of 5.0 (1.5-9.5). After a median follow-up of 30 (12-118) months, the median EDSS score improved to 2.0 (0-6.5,

conclusionAHSCT is safe and effective as a first-line DMT in inducing rapid and sustained remission in patients with 'aggressive' MS.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple SclerosisHumansRetrospective StudiesTransplantation, AutologousTreatment Outcomeaggressive multiple sclerosisAutologous haematopoietic stem cell transplantationdisease-modifying therapymultiple sclerosisno evidence of disease activity

Identifiers

PMID33565902
PMCPMC8226372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.